IMMXImmix Biopharma, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $11.92 · now $11.92 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, IMMX has typically landed between $8.29 and $19.79 — a range of −30.4% to +66.0% from the issuance price $11.92.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,169 overlapping 1 month windows · 2021-12-162026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($11.92) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where IMMX has typically landed a month from the 2026-09-16 close of $11.92 — the range is history, not a prediction.

$8.29worst · -30.4%$19.79best · +66.0%
  • now $11.92 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $11.92 (+0.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $9.69$14.15
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.29$19.79
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,169 windows spanning 2021-12-16 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-02-09−62.3%−62.3%+0.0%
2022-02-08−61.2%−61.2%+2.3%
2022-02-07−58.7%−60.8%+2.7%
3 best
2025-11-11+128.5%+0.0%+128.5%
2022-04-27+123.3%−2.3%+123.3%
2022-12-05+117.9%−10.3%+117.9%

1,169 overlapping windows · 2021-12-162026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
60%
−3.5%
n=5
Feb
20%
−5.7%
n=5
Mar
20%
−6.5%
n=5
Apr
40%
−2.5%
n=5
May
60%
+9.2%
n=5
Jun
60%
+10.3%
n=5
Jul
40%
−2.6%
n=5
Aug
40%
+5.4%
n=5
Sep
20%
−1.6%
n=5
Oct
75%
+17.1%
n=4
Nov
100%
+26.5%
n=4
Dec
100%
+38.0%
n=4

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$14$22025-12-10: 2 insider purchases, $10K — Morris Gabriel S, Rachman Ilya M2025-09-17: 1 insider purchase, $5K — Rachman Ilya M2025-09-16: 1 insider purchase, $5K — Morris Gabriel S2025-09: 2 open-market purchases, $10K2025-12: 2 open-market purchases, $10K↑ buys↓ salesdirector Morris Gabriel S — Purchase on 2025-12-10, filed same daydirector Rachman Ilya M — Purchase on 2025-12-10, filed same daydirector Rachman Ilya M — Purchase on 2025-09-17, filed same daydirector Morris Gabriel S — Purchase on 2025-09-16, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-12-10Morris Gabriel SdirectorPurchase770 @ $6.58$5K+0.3% of holding−35.4%+17.1%291,429Form 4 · filed same day
2025-12-10Rachman Ilya MdirectorPurchase746 @ $6.67$5K+0.1% of holding−35.4%+17.1%1,141,683Form 4 · filed same day
2025-09-17Rachman Ilya MdirectorPurchase2,500 @ $2.02$5K+0.2% of holding+37.3%+393.2%1,140,937Form 4 · filed same day
2025-09-16Morris Gabriel SdirectorPurchase2,600 @ $1.97$5K+0.9% of holding+29.9%+372.2%290,659Form 4 · filed 1 day after the trade
2024-12-23Hsu JasondirectorPurchase40,000 @ $2.19$88K+4.7% of holding−12.7%−4.5%893,000Form 4 · filed 3 days after the trade
2024-12-20Hsu JasondirectorPurchase7,700 @ $2.17$17K+0.9% of holding−8.4%−0.9%853,000Form 4 · filed 6 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

28 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-05-22Adams Helen C.directorAward / grant6,250181,004Form 4
2026-05-22Adams Helen C.directorAward / grant12,50012,500Form 4
2026-05-22BUCHAN JANEdirectorAward / grant6,25028,705Form 4
2026-05-22BUCHAN JANEdirectorAward / grant12,50012,500Form 4
2026-05-22CHANG NANCY TdirectorAward / grant6,250428,190Form 4
2026-05-22CHANG NANCY TdirectorAward / grant12,50012,500Form 4
2026-05-22Chudnovsky YekaterinadirectorAward / grant6,2506,250Form 4
2026-05-22Chudnovsky YekaterinadirectorAward / grant12,50012,500Form 4
2026-05-22Hsu JasondirectorAward / grant6,250899,250Form 4
2026-05-22Hsu JasondirectorAward / grant12,50012,500Form 4
2026-05-22Rachman Ilya MdirectorAward / grant500,000500,000Form 4
2026-05-22Marquet MagdadirectorAward / grant6,25052,342Form 4
2026-05-22Marquet MagdadirectorAward / grant12,50012,500Form 4
2026-05-22Morris Gabriel SdirectorAward / grant500,000500,000Form 4
2026-05-22Ng CareydirectorAward / grant6,25026,250Form 4
2026-05-22Ng CareydirectorAward / grant12,50012,500Form 4
2025-12-08Morris Gabriel SdirectorExercise156,000426,844Form 4
2025-12-08Morris Gabriel SdirectorExercise60,0000Form 4
2025-12-08Morris Gabriel SdirectorExercise96,0000Form 4
2025-11-21CHANG NANCY TdirectorAward / grant39,64339,643Form 4
2025-06-20Ng CareydirectorAward / grant33,00033,000Form 4
2025-06-20Rachman Ilya MdirectorAward / grant340,000340,000Form 4
2025-06-20Morris Gabriel SdirectorAward / grant340,000340,000Form 4
2025-06-20Adams Helen C.directorAward / grant33,00033,000Form 4
2025-06-20Hsu JasondirectorAward / grant33,00033,000Form 4
2025-06-20BUCHAN JANEdirectorAward / grant33,00033,000Form 4
2025-06-20Chudnovsky YekaterinadirectorAward / grant33,00033,000Form 4
2025-06-20Marquet MagdadirectorAward / grant33,00033,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.